Fig. 4

Therapeutic effects of CCL11-E6E7 relies on CD8 + T, NK and CCR3 + cells for durable tumor inhibition. A and B The mice (n = 6 for each group) were each inoculated with 2 × 10⁵ TC-1 tumor cells which express HPV16 E6 and E7 protein. After 7 days, the mice were treated with CCL11-E6E7 plasmid alone or combined with anti-CD4, anti-CD8, or anti-NK 1.1 administration every three days for a total of 7 times. Following treatment, the percentage of E7-specific CD8 + T-cells in the peripheral blood were analyzed by Fluorescence activated cell sorting (FACS) analysis (A) and the growth of tumors is regularly measured and plotted as a curve (B). Data are presented as means ± SEM. C and D-E On the 7th day after being grafted with 2 × 10.⁵ TC-1 tumor cells subcutaneously, the mice are grouped (n = 7 for each group,) according to tumor size and treated with XCL1-E6E7 or CCL11-E6E7 with or without anti-CCR3 monoclonal antibody injection intraperitoneally. FACS analysis on peripheral blood was conducted to evaluate the percentage of E7-specific CD8 + T-cells at 14 days post immunization whose data are presented as means ± SEM (C).Kinetics of tumor growth are shown as means ± SEM for each group and the complete remission ratio was indicated (D-E)